-
-
-
-
-
-
-
Corcept's relacorilant meets survival endpoint in ovarian cancer trial
-
-
-
-
-
-
-
Wolfe Research Starts Corcept Therapeutics (CORT) at Peerperform
-
-
-
-
-
-
-
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
-
-
-
-
-
-
-
Corcept Therapeutics (CORT): FDA Files New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
-
-
-
-
15,416 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

